Program 27 September 2023

07.30-08.30 | REGISTRATION

08.30-9.15 | mRNA platform approach for the preclinical development of vaccines | Shambhunath Choudhary
9.15-10.00 | Next generation bispecific antibodies and antibody fusion proteins for cancer immunotherapy | Christian Klein

10.00-10.30 | COFFEE BREAK - POSTERS - EXHIBITION

10.30-11.15 | Biologic Associated Immune-mediated Renal Disorders in nonclinical toxicity studies and their relationship to the clinical syndrome.of BAIRD | Ken Frazier
11.15-11.45 | Immune-mediated ocular changes with biologics in nonclinical safety studies | Elke-Astrid Atzpodien & Christian Freichel

11.45-13.15 | LUNCH - POSTERS - EXHIBITION

13.15-14.00 | General GCT, focus on tox/path, and patient | Jonathan Appleby
14.00-14.45 | The comprehensive pathologist toolbox for the preclinical development of AAV-based gene therapy products | Basel Assaf
14.45-15.30 | Liver gene transfer and editing: challenges and perspectives | Alessio Cantore

15.30-16.00 | COFFEE BREAK - POSTERS - EXHIBITION

16.00-16.30 | General biopharmaceutical/regulatory/clinical aspects of Gene Therapies including rAAV vectors | Andreas Hartmann
16.30-17.15 | Development of PLX-R18 Cell Therapy as a Countermeasure for Hematopoietic Acute Radiation Syndrome | Marianna Truman
17.15-18.00 | Gene-modified differentiated lymphocytes (cell therapy) | Jan Klapwijk